Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xylometazoline is a direct-acting alpha-adrenergic agonist and imidazole derivative used as a topical nasal decongestant. It works by binding to alpha-adrenergic receptors in the nasal mucosa to cause vasoconstriction of blood vessels. This reduces swelling and congestion associated with conditions such as the common cold, allergic rhinitis (hay fever), and sinusitis. Its sympathomimetic action leads to rapid relief of nasal stuffiness but should not be used for more than 7–10 days due to risk of rebound congestion (rhinitis medicamentosa). It is available over-the-counter in many countries as sprays or drops[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xylometazoline.